Literature DB >> 21334733

Significance of numbers of metastatic and removed lymph nodes in FIGO stage IB1 to IIA cervical cancer: Primary surgical treatment versus neoadjuvant chemotherapy before surgery.

Hee Seung Kim1, Ji Hyun Kim, Hyun Hoon Chung, Hak Jae Kim, Yong Beom Kim, Jae Weon Kim, Noh Hyun Park, Yong Sang Song, Soon-Beom Kang.   

Abstract

OBJECTIVE.: The objective of this study was to compare the significance of numbers of metastatic (MLN) and removed lymph nodes (RLN) between primary surgical treatment (PST) and neoadjuvant chemotherapy followed by surgery (NCS) in patients with FIGO stage IB1 to IIA cervical cancer. METHODS.: Among 1124 patients with cervical cancer, PST (n=451) and NCS (n=73) groups were enrolled for evaluating the association between numbers of MLN and RLN, and clinical outcomes including the pattern of recurrence and survival according to the 2 treatments. RESULTS.: Mean values of progression-free survival (PFS) were 100.8 vs. 87.6 vs. 57.7 months in 0 vs. 1-2 vs. ≥3 MLN, suggesting that ≥3 MLN was associated with poor PFS (adjusted HR, 2.71; 95% CI, 1.02 to 7.21). However, there was no association between the number of MLN and survival in NCS group. The increased number of MLN was also associated with the increase of distant metastasis in PST group (44.0% vs. 72.7% vs. 78.6%; p=0.02), whereas there was no association between the number of MLN and the pattern of recurrence in NCS group. Moreover, mean values of PFS were 57.2 (<20 RLN) vs. 77.9 months (≥20 RLN) in PST group with lymph node metastasis (p=0.04), demonstrating that ≥20 RLN improved PFS in PST group (adjusted HR, 0.48; 95% CI, 0.25 to 0.95). CONCLUSIONS.: The increased number of MLN may be more significant for predicting poor survival and distant metastasis, and the increased number of RLN may be associated with better survival in the patients treated with PST than those treated with NCS.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21334733     DOI: 10.1016/j.ygyno.2011.01.024

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  17 in total

1.  The safety and efficacy of the preoperative neoadjuvant chemotherapy for patients with cervical cancer: a systematic review and meta analysis.

Authors:  Du He; Chunyan Duan; Jun Chen; Lin Lai; Jiaquan Chen; Dian Chen
Journal:  Int J Clin Exp Med       Date:  2015-09-15

2.  Risk Stratification Based on Metastatic Pelvic Lymph Node Status in Stage IIIC1p Cervical Cancer.

Authors:  Anyang Li; Luhui Wang; Qi Jiang; Wenlie Wu; Baoyou Huang; Haiyan Zhu
Journal:  Cancer Manag Res       Date:  2020-07-28       Impact factor: 3.989

3.  Could the extent of lymphadenectomy be modified by neoadjuvant chemotherapy in cervical cancer? A large-scale retrospective study.

Authors:  Ting Hu; Xiong Li; Qinghua Zhang; Kecheng Huang; Yao Jia; Ru Yang; Fangxu Tang; Qiang Tian; Ding Ma; Shuang Li
Journal:  PLoS One       Date:  2015-04-10       Impact factor: 3.240

4.  Development and validation of a surgical-pathologic staging and scoring system for cervical cancer.

Authors:  Shuang Li; Xiong Li; Yuan Zhang; Hang Zhou; Fangxu Tang; Yao Jia; Ting Hu; Haiying Sun; Ru Yang; Yile Chen; Xiaodong Cheng; Weiguo Lv; Li Wu; Jin Zhou; Shaoshuai Wang; Kecheng Huang; Lin Wang; Yuan Yao; Qifeng Yang; Xingsheng Yang; Qinghua Zhang; Xiaobing Han; Zhongqiu Lin; Hui Xing; Pengpeng Qu; Hongbing Cai; Xiaojie Song; Xiaoyu Tian; Jian Shen; Ling Xi; Kezhen Li; Dongrui Deng; Hui Wang; Changyu Wang; Mingfu Wu; Tao Zhu; Gang Chen; Qinglei Gao; Shixuan Wang; Junbo Hu; Beihua Kong; Xing Xie; Ding Ma
Journal:  Oncotarget       Date:  2016-04-12

5.  Systematic review and meta-analysis of the prognostic significance of microRNAs in cervical cancer.

Authors:  Zhilan Chen; Yingyan Han; Chengwen Song; Huafang Wei; Ying Chen; Kecheng Huang; Shuang Li; Ding Ma; Shixuan Wang; Jing Wang; Qiping Lu
Journal:  Oncotarget       Date:  2017-12-16

6.  Neoadjuvant chemotherapy with radical surgery vs radical surgery alone for cervical cancer: a systematic review and meta-analysis.

Authors:  Hui Zhao; Yue He; Shu-Li Yang; Qun Zhao; Yu-Mei Wu
Journal:  Onco Targets Ther       Date:  2019-03-07       Impact factor: 4.147

7.  Combining the negative lymph nodes count with the ratio of positive and removed lymph nodes can better predict the postoperative survival in cervical cancer patients.

Authors:  Ying Chen; Lei Zhang; Jing Tian; Xiubao Ren; Quan Hao
Journal:  Cancer Cell Int       Date:  2013-02-01       Impact factor: 5.722

8.  The impact of examined lymph node count on survival in squamous cell carcinoma and adenocarcinoma of the uterine cervix.

Authors:  Juan Zhou; Wen-Wen Zhang; San-Gang Wu; Zhen-Yu He; Jia-Yuan Sun; Yan Wang; Qiong-Hua Chen
Journal:  Cancer Manag Res       Date:  2017-07-18       Impact factor: 3.989

9.  Adjuvant chemotherapy after surgery can improve clinical outcomes for patients with IB2-IIB cervical cancer with neoadjuvant chemotherapy followed by radical surgery.

Authors:  Haiying Sun; Kecheng Huang; Fangxu Tang; Xiong Li; Xiaoli Wang; Sixiang Long; Shasha Zhou; Jianwei Zhang; Ruoqi Ning; Shuang Li; Shixuan Wang; Ding Ma
Journal:  Sci Rep       Date:  2018-04-24       Impact factor: 4.379

10.  Comparison of different lymph node staging systems in patients with node-positive cervical squamous cell carcinoma following radical surgery.

Authors:  Qinhao Guo; Jun Zhu; Yong Wu; Hao Wen; Lingfang Xia; Min Yu; Simin Wang; Xingzhu Ju; Xiaohua Wu
Journal:  J Cancer       Date:  2020-10-23       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.